These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 23701526)

  • 1. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
    Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
    Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Injectable extended-release naltrexone for opioid dependence: an open label study of long-term safety and efficacy].
    Krupitsky EM; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Blokhina EA; Silverman BL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):49-56. PubMed ID: 25591636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
    Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
    Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
    Krupitskiĭ EM; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Blokhina EA; Silverman BL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5 Pt 2):3-11. PubMed ID: 22951790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
    Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
    Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
    Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
    Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence.
    Earley PH; Zummo J; Memisoglu A; Silverman BL; Gastfriend DR
    J Addict Med; 2017; 11(3):224-230. PubMed ID: 28358754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
    Mannelli P; Wu LT; Peindl KS; Swartz MS; Woody GE
    Drug Alcohol Depend; 2014 May; 138():83-8. PubMed ID: 24602363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
    Lee JD; Nunes EV; Novo P; Bachrach K; Bailey GL; Bhatt S; Farkas S; Fishman M; Gauthier P; Hodgkins CC; King J; Lindblad R; Liu D; Matthews AG; May J; Peavy KM; Ross S; Salazar D; Schkolnik P; Shmueli-Blumberg D; Stablein D; Subramaniam G; Rotrosen J
    Lancet; 2018 Jan; 391(10118):309-318. PubMed ID: 29150198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.
    Syed YY; Keating GM
    CNS Drugs; 2013 Oct; 27(10):851-61. PubMed ID: 24018540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
    Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
    J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.
    Lee JD; Friedmann PD; Boney TY; Hoskinson RA; McDonald R; Gordon M; Fishman M; Chen DT; Bonnie RJ; Kinlock TW; Nunes EV; Cornish JW; O'Brien CP
    Contemp Clin Trials; 2015 Mar; 41():110-7. PubMed ID: 25602580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
    Nunes EV; Bisaga A; Krupitsky E; Nangia N; Silverman BL; Akerman SC; Sullivan MA
    Addiction; 2020 Feb; 115(2):239-246. PubMed ID: 31313402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).
    Kunøe N; Opheim A; Solli KK; Gaulen Z; Sharma-Haase K; Latif ZE; Tanum L
    BMC Pharmacol Toxicol; 2016 Apr; 17(1):18. PubMed ID: 27121539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
    Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
    Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
    Nunes EV; Krupitsky E; Ling W; Zummo J; Memisoglu A; Silverman BL; Gastfriend DR
    J Addict Med; 2015; 9(3):238-43. PubMed ID: 25901451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
    Comer SD; Mannelli P; Alam D; Douaihy A; Nangia N; Akerman SC; Zavod A; Silverman BL; Sullivan MA
    Am J Addict; 2020 Jul; 29(4):313-322. PubMed ID: 32246728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners.
    Gordon MS; Kinlock TW; Vocci FJ; Fitzgerald TT; Memisoglu A; Silverman B
    J Subst Abuse Treat; 2015 Dec; 59():52-8. PubMed ID: 26299956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.
    Jarvis BP; Holtyn AF; Berry MS; Subramaniam S; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    J Subst Abuse Treat; 2018 Feb; 85():38-44. PubMed ID: 28449955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.